Clinical Trial

A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis

Name: A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis — clinical trial record (NCT07150988)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.

Trial Details

NCT Number	NCT07150988
Lead Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Conditions	Psoriasis
Enrollment	150 participants
Start Date	2025-09-26
Primary Completion	2026-11-06 (estimated)
Study Completion	2026-11-06 (estimated)
Updated on ClinicalTrials.gov	2025-09-02